ArticleFrontiers in genetics2025
Systematic analysis of anoikis-related genes identifies SRPX2-FAK/AKT-IL-6 axis in the progression and peritoneal metastasis of gastric cancer.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Peritoneal metastasis (PM) remains a primary cause of poor prognosis in advanced gastric cancer (GC). While anoikis resistance enables detached tumor cells to survive and promotes invasion and metastasis, its specific mechanisms in GC related PM are not yet fully understood. Methods: Anoikis related differentially expressed genes were identified using GC samples from the TCGA and GEO databases. Molecular subtypes were characterized by non negative matrix factorization (NMF) clustering. Survival outcomes were assessed via Kaplan-Meier analysis, and functional profiles were evaluated through pathway enrichment scoring. A prognostic risk model was constructed by combining weighted gene co expression network analysis (WGCNA) with Lasso-Cox regression. For PM diagnosis, characteristic genes were screened using support vector machine (SVM) and random forest (RF) algorithms to build a diagnostic model. Experimental validation was performed to confirm the expression and functional role of SRPX2. Results: GC was stratified into two molecular subtypes. Subtype A showed marked enrichment of anoikis resistance related factors and was associated with significantly poorer prognosis. A six gene prognostic signature (HEYL, SRPX2, LBH, PLAT, ITGAV, HTRA1) was established and validated externally. A nine gene diagnostic panel (SLC30A9, ZFHX4, CYTB, NDFIP2, NMNAT2, SRPX2, TBC1D8B, CLEC3B, CHRDL2) was also constructed for PM. SRPX2 was identified as an independent prognostic marker and a PM associated biomarker, highly expressed in cancer associated fibroblasts (CAFs). Functional studies demonstrated that SRPX2 promotes GC progression and peritoneal metastasis by activating the FAK/AKT pathway and IL-6 paracrine signaling, thereby inducing anoikis resistance. Discussion: This study proposes an anoikis based molecular classification of GC and develops both prognostic and diagnostic models for PM. It further reveals that SRPX2 driven anoikis resistance, mediated through the FAK/AKT-IL-6 axis, facilitates peritoneal metastasis. These findings provide new directions for prognostic assessment and therapeutic strategies in gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.